CTO
Jay S. Stout, PhD is the Chief Technology Officer (CTO) at Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company developing therapies targeting the neonatal Fc receptor for autoimmune diseases.[[1]](https://www.insidertrades.com/immunovant-inc-stock/jay-s-stout/)[[2]](https://www.marketbeat.com/instant-alerts/immunovant-nasdaqimvt-cto-jay-stout-sells-1203-shares-2026-01-09/)[[4]](https://theorg.com/org/immunovant/org-chart/jay-s-stout) In this role, he oversees technical operations, with recent insider trading activity including the sale of 1,203 shares on January 7, 2026, at an average price of $26.53, leaving him with 199,611 shares valued at approximately $5.3 million.[[2]](https://www.marketbeat.com/instant-alerts/immunovant-nasdaqimvt-cto-jay-stout-sells-1203-shares-2026-01-09/)[[3]](https://www.investing.com/news/insider-trading-news/immunovant-cto-stout-sells-32k-in-imvt-stock-93CH-4440530) As of late 2025, he owned 200,814 shares worth over $4.77 million.[[1]](https://www.insidertrades.com/immunovant-inc-stock/jay-s-stout/)
Dr. Stout brings extensive experience in biopharmaceutical technical operations and scale-up. Prior to rejoining Immunovant, he served as an independent consultant from 2020 to April 2023, supporting late-stage products in immunology, cell, and gene therapy.[[1]](https://www.insidertrades.com/immunovant-inc-stock/jay-s-stout/)[[4]](https://theorg.com/org/immunovant/org-chart/jay-s-stout) From June 2018 to January 2021, he led Technical Operations at Immunomedics (acquired by Gilead), contributing to the approval of an antibody drug conjugate for oncology.[[1]](https://www.insidertrades.com/immunovant-inc-stock/jay-s-stout/) He has held senior leadership roles at Versartis (Aravive), SanBio, Merck, Amgen, Pfizer, and BioNebraska (Restoragen), with a proven track record in biologic approvals for monoclonal antibodies, antibody drug conjugates, and cell and gene therapies.[[1]](https://www.insidertrades.com/immunovant-inc-stock/jay-s-stout/) Dr. Stout earned a B.S. and M.S. in Chemistry from the University of Iowa and a Ph.D. in Chemistry and Biochemistry from the University of Nebraska-Lincoln, and he chaired the Amgen Center for BioProcessing Advisory Board at Keck Graduate Institute from 2021-2023.[[1]](https://www.insidertrades.com/immunovant-inc-stock/jay-s-stout/)
View full insider profile →
